Samsara Biocapital, LLC reported 24 holdings worth US$1.22B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Samsara Biocapital, LLC reported 24 holdings worth US$1.22B as of Jun 30, 2026. Largest: Scholar Rock Holding Corporation, Alumis Inc. and Mineralys Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 24
- Value as reported
- US$1.22B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Scholar Rock Holding Corporation | 6.9M | US$379M | 31.2% |
| Alumis Inc. | 6.35M | US$179M | 14.7% |
| Mineralys Therapeutics, Inc. | 5.87M | US$158M | 13.0% |
| Septerna, Inc. | 3.15M | US$105M | 8.7% |
| Alamar Biosciences, Inc. | 2.48M | US$67.2M | 5.5% |
| Neurogene Inc. | 1.72M | US$54M | 4.4% |
| Kalaris Therapeutics, Inc. | 12.9M | US$52.4M | 4.3% |
| Spyglass Pharma, Inc. | 2.11M | US$47M | 3.9% |
| Sutro Biopharma, Inc. | 1.06M | US$35.3M | 2.9% |
| Inventiva Sa | 6.31M | US$23.9M | 2.0% |
| Jade Biosciences, Inc. | 736K | US$16.4M | 1.3% |
| Parabilis Medicines, Inc. | 556K | US$15.2M | 1.3% |
| Vtv Therapeutics Inc. | 298K | US$11.2M | 0.92% |
| Aquestive Therapeutics, Inc. | 2.5M | US$10.4M | 0.85% |
| Nkarta, Inc. | 3.51M | US$9.93M | 0.82% |
| Artiva Biotherapeutics, Inc. | 955K | US$9.26M | 0.76% |
| Rani Therapeutics Holdings, Inc. | 10.4M | US$7.88M | 0.65% |
| Abivax Sa | 55,095 | US$7.34M | 0.60% |
| X4 Pharmaceuticals, Inc. | 1.4M | US$6.52M | 0.54% |
| Eloxx Pharmaceuticals, Inc. | 400K | US$5.55M | 0.46% |
| Coherus Oncology, Inc. | 3.43M | US$4.8M | 0.39% |
| Upstream Bio, Inc. | 354K | US$2.45M | 0.20% |
| Gossamer Bio, Inc. | 7.22M | US$1.19M | 0.10% |
| Palvella Therapeutics, Inc. | 0 | US$0 | 0.00% |